# Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease

> **NCT01806610** · PHASE2 · WITHDRAWN · sponsor: **Ultragenyx Pharmaceutical Inc**

## Conditions studied

- Chronic-kidney Disease Stage 5D on Stable Hemodialysis

## Interventions

- **DRUG:** BPS804
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01806610
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-08
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2022-09-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01806610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01806610, "Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01806610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*